Skip to main content

Deschatelets Pascal's Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed Apr 9, 2024

Accession no.
0001127602-24-012710
Filed
Apr 9, 2024
Trade date
Apr 8, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.74M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Deschatelets PascalCIK 0001657720Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 8, 2024Common StockMOption exerciseAcquired+69,107$3.76+$259,842.321,185,090Direct
Apr 8, 2024Common StockSSaleDisposed−64,379$54.12−$3,484,191.481,120,711Direct
Apr 8, 2024Common StockSSaleDisposed−4,728$54.92−$259,661.761,115,983Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 8, 2024Common StockMOption exerciseDisposed−69,107$0.00$037,280Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)